Tracer library / [18F]AlF-3p-C-NETA-ePSMA-16

[18F]AlF-3p-C-NETA-ePSMA-16

Also written as [F-18]AlF-3p-C-NETA-ePSMA-16

Radionuclide: F-18 t½ 109.77 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer Preclinical only, no clinical indication yet

What it is

Compound class: PSMA-targeting agent with 3p-C-NETA chelator (urea-based PSMA ligand)
Target / mechanism: PSMA-targeting PMID 37375829
Clinical application: Imaging and treatment of prostate cancer PMID 37375829
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
AllinOne (AiO) Trasis	—	—	40%	97.4%	3p-C-NETA-ePSMA-16	37375829 2023 Pharmaceuticals (Basel) [18F]AlF-3p-C-NETA-ePSMA-16 was radiolabeled in an automated AllinOne® synthesis module (Trasis, Liège, Belgium) - [18F]AlF-3p-C-NETA-ePSMA-16 was obtained with good RCC (40%, n = 1) and 97.4% RCP

Need this precursor?We can point you to suppliers for [18F]AlF-3p-C-NETA-ePSMA-16, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37375829. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37375829: '3p-C-NETA-ePSMA-16'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: F-18 is a positron emitter used only for PET imaging. Linked articles: PMID 37375829. Stage set/updated at stage 39 from PMID 37375829: 'dynamic PET/CT scans performed after administration of [18F]AlF-3p-C-NETA-ePSMA-16 in PC3-Pip tumor xenografted mice resulted in a better tumor visualization and imaging contrast'.